Compare GSK plc (GSK) vs SAP SE (SAP) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

SAP trades at $159.71, up 3.17% today, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $36.80B and net income margin of 19.58%, while analyst consensus remains bullish with a $228.50 price target. Recent news highlights EU antitrust resolution and AI-driven transformation efforts.

Outlook is mixed: solid profitability and growth support upside, but technical weakness and competitive pressures pose risks. Investment opportunity hinges on execution of AI initiatives and cloud transition, balanced against macroeconomic and sector volatility.